All articles

Melanotan II began as 1980s melanoma-prevention research at the University of Arizona — an injectable sunscreen. The origin story of the tanning peptide.

How a University of Arizona peptide became two FDA drugs and a gray-market staple: the patent trail from Hruby and Hadley to Clinuvel and Palatin.

Melanotan II's recipe was published in journals and patents, then orphaned by its developers. Public structure plus real demand made the gray market inevitable.

Melanotan I vs Melanotan II: near-identical peptides from the same Arizona lab. One became an approved medicine; the other, the gray market's favorite. Why.

A University of Arizona self-experiment with Melanotan II produced an eight-hour erection — and pointed the way to an FDA-approved libido drug.

Why Melanotan II tans, suppresses appetite, and affects libido at once: one non-selective agonist hitting all five melanocortin receptors.

Melanotan and melatonin are one letter apart and nothing else alike: a sleep supplement versus an unapproved tanning peptide. Why the mix-up matters.

Melanotan II is sold as a 'natural' hormone your body already makes. It mimics α-MSH — but your body keeps that signal local and brief for a reason.

'Melanotan prevents skin cancer' is a caption-level fact. The trials never tested that. What the evidence shows, what the claim sells, and the gap between.

Why one dose of Melanotan II tans, sickens, and arouses at once: its pharmacokinetics give it no address. It floods the body and outlasts the signal it mimics.

Red hair is the loud end. Most MC1R variants are quieter: r alleles, heterozygotes, East Asian R163Q. A future agonist would not reach everyone who burns.

A tan is the body's sunscreen: eumelanin absorbing UV before it reaches DNA. How melanin protects skin — and why that was Melanotan's target.

A suntan is a wound response: pigment made only after UV has damaged skin DNA. Melanotan's idea was the protection without the damage.

Red hair, freckles, and burning instead of tanning trace to one receptor: MC1R. The keyhole every Melanotan was cut to fit — and a melanoma risk gene.

For most of history a tan meant labor; then, in one decade, it flipped. How Chanel, the Riviera, and the sunbed made tanned skin aspirational.

Melanotan II sold as a capsule, gummy, or drink can't work: a cyclic peptide doesn't survive digestion. What 'oral melanotan' actually is.

Research-chemical storefronts, banned hashtags, influencer commissions, salon shelves, disguised payments — the supply machine that sells Melanotan II now.

UV light makes skin manufacture its own opioid — the hidden reward inside every tan. The science of tanning dependence, and what it says about Melanotan.

How Melanotan II went viral: nasal sprays, flavored drops, and the TikTok 'vacation peptide' re-packaged an unregulated injectable for the open market.

Why Melanotan II became the most self-injected unapproved drug: it served a want, not a need — and wants don't wait for clinical trials.

Never approved anywhere, Melanotan II sold anyway — through forums, gyms, and 'research chemical' sites. How the gray market formed, and what it costs.

Online Melanotan II guides carry titration schedules, reconstitution math, maintenance plans. The numbers are theatre — arithmetic on an unknown vial.

Wellness clinics now sell Melanotan II as a longevity peptide. Real melanocortin drugs exist — approved, selective, monitored. This isn't one of them.

Regulators seized sites, parcels, and sellers. Australia made possession a crime. The market moved to nasal sprays. Why enforcement keeps losing.

Melanotan II darkens and multiplies moles — and the deeper danger is diagnostic: the case reports, the melanoma question, and the signals you lose.

Melanotan II side effects, sorted by evidence: the documented acute and pigment effects, and the rare serious events that reach the medical literature.

Gray-market Melanotan II comes from unknown labs: purity, sterility, and dose are all assumptions — and assumptions have sent people to the ER.

Afamelanotide (Scenesse) is an approved melanocortin drug that protects skin from light — locked in a rare-disease label. Why, and what a breakout would take.

Clinuvel profits from a rare-disease implant. Novo funds prevention trials insurers pay for. A general-public sun drug needs both, and has neither.

How a photoprotective melanocortin drug could reach everyone: beachhead indications, from approved EPP to a vitiligo trial now in Phase III.

Proving a drug prevents skin cancer needs one of the longest, largest trials in medicine. Why the evidence bar — not the chemistry — is the real wall.

Is Melanotan II legal in the U.S.? It's unapproved — but the technology isn't. The three doors: FDA approval, compounding, and the gray market.

The four requirements a general-public photoprotective drug must clear — and how far today's science already is toward each. Analysis, labeled as such.